Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Efficacy and Safety of Telitacicept in Immune Kidney Disease
ChiCTR2600121420Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept in IgA nephropathy (IgAN), idiopathic membranous glomerulonephritis (IMG), lupus nephritis (LN) and 1 more (3 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Complete Remission Rate of Proteinuria at Week 24. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)idiopathic membranous glomerulonephritis (IMG)lupus nephritis (LN)Immune-mediated kidney disease (IMKD)
Beyond the preview
Go deeper on ChiCTR2600121420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121420.